Where the evidence runs out
Research peptides such as BPC-157 and TB-500 have no approved label anywhere, so no regulator has published a contraindication list for them, and human safety data are limited for everyone. The four groups below are the ones in which that unknown matters most. Each is a reason to see a licensed Philippine physician before anything else.
Semaglutide · Tirzepatide
The US prescribing information for semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) carries a boxed warning on thyroid C-cell tumours and sets out who should not use them, on top of the general list. These are prescription medicines, and prescribing belongs with a licensed Philippine physician. Retatrutide has no approved label anywhere, so no official exclusion list exists for it.
Nothing on this page is medical clearance, and the screening questions above are the ones worth taking to a licensed Philippine physician before anything else. On the sourcing side, our partner and supplier lists research vials in pesos. View the Primara Labs catalogue
Healing peptides: relative cautions
The highest level of human evidence found for BPC-157 is small human studies, and for TB-500 it is animal and cell. No trial has established the safety of either in people. The two situations below warrant a physician conversation.
Consult-first triggers
Any of the following is a reason to see a licensed Philippine physician before any peptide. None is an automatic exclusion.
For the physician visit
The six questions this page covers, in one list. A clear answer to all six is not medical clearance. It is the list to take to a licensed Philippine physician.
Continue the induction
Educational reference only. Not medical advice. The lists above are starting points for a conversation with a licensed Philippine physician about an individual medical history.
